Albany Molecular Research (AMRI) Posts Q3 Loss of $0.02, Tops by 2c; Guides
AMRI Hot Sheet
Revenue Growth %: -5.6%Financial Fact:
Research and development: 373K
Today's EPS Names:
VSNT, CIM, KH, More
Albany Molecular Research (NASDAQ: AMRI) reports Q3 loss of $0.02, 2 cents better than the analyst estimate of ($0.04). Revenue for the quarter was $47.70 million, which compares to the estimate of $46.27 million.
Sees Q409 revs of $32 - $36 million, and FY09 revs of $154 - $158 million. Consensus sees $47.93 million and $199.54 million, respectively.
Also sees Q409 loss of $0.06 - $0.10, and FY09 loss of $0.01 - $0.05. Consensus sees ($0.03) and $0.05 respectively.
Sees Q409 revs of $32 - $36 million, and FY09 revs of $154 - $158 million. Consensus sees $47.93 million and $199.54 million, respectively.
Also sees Q409 loss of $0.06 - $0.10, and FY09 loss of $0.01 - $0.05. Consensus sees ($0.03) and $0.05 respectively.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
- Hewlett-Packard Company (HPQ) Tops Q2 EPS by 7c; Guides Q3 Below the Street, Raises FY12 Outlook
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
